Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is reporting third quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, KPTI is expected to report 3Q20 loss of $ 0.72 per share from revenue of $ 21.45 million.
For the full year, analysts anticipate top line of $ 110.03 million, while looking forward to loss of $ 2.75 per share bottom line.
Previous Quarter Performance
Karyopharm Therapeutics Inc. outlined loss for the second quarter of $ 0.63 per share, from the revenue of $ 33.51 million. The quarterly revenues increased 37,133.33 percent compared with the same quarter last year. Street analysts expected Karyopharm Therapeutics Inc. to report loss of $ 0.58 per share on revenue of $ 27.42 million for the second quarter. The bottom line results missed street analysts by $ 0.05 or 8.62 percent, at the same time, top line results outshined analysts by $ 6.09 million or 22.21 percent.
Stock Performance
On Friday, shares of Karyopharm Therapeutics Inc. has traded high as $ 15.58 and has cracked $ 14.67 on the downward trend, reaching $ 14.82 with volume of 1.10 million shares.
According to the previous trading day, closing price of $ 14.82, representing a 19.08 % increase from the 52 week low of $ 13.10 and a 47.32 % decrease over the 52 week high of $ 29.61.
The company has a market capital of $ 1.09 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Karyopharm Therapeutics Inc. will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.karyopharm.com
Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor), which has received approval from the Food and Drug Administration in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma, as well as is under review by the European Medicines Agency.
